← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Attagene, Inc.
Research Triangle Park, NC
$20,391,445
Total funding
7
Grants
Funding over time
peak $2.4M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,391,445 · 7
By mechanism
U01$11,467,383 · 1
R44$7,990,155 · 4
R43$933,907 · 2
Investigators at Attagene, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Identification of TLR signaling network$2,352,579
U01 · FY2006 · AI
Identification of TLR signaling network$2,326,024
U01 · FY2007 · AI
Identification of TLR signaling network$2,325,818
U01 · FY2008 · AI
Identification of TLR signaling network$2,242,952
U01 · FY2005 · AI
Identification of TLR signaling network$2,220,010
U01 · FY2004 · AI
Predicting DILI liability by transcription factor profiling$1,025,137
R44 · FY2018 · GM
Predicting DILI liability by transcription factor profiling$1,016,149
R44 · FY2017 · GM
Assigning mode of action to phenotypically discovered anticancer leads.$1,000,000
R44 · FY2024 · CA
Assigning mode of action to phenotypically discovered anticancer leads.$1,000,000
R44 · FY2023 · CA
A Two-Tier Effect-Based Water Bioactivity Surveillance System.$999,999
R44 · FY2025 · ES
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling$999,998
R44 · FY2021 · GM
Assessing the polypharmacology of kinase inhibitors by transcription factor activity profiling$999,998
R44 · FY2020 · GM
Predicting DILI liability by transcription factor profiling$707,364
R44 · FY2019 · GM
Novel biosensors for toxicological applications$321,374
R43 · FY2003 · CA
Novel biosensors for toxicological applications$320,149
R43 · FY2004 · CA
Predicting DILI liability by transcription factor profiling$241,510
R44 · FY2018 · GM
Profiling of signal transduction pathways in cancer$146,750
R43 · FY2003 · CA
Profiling of signal transduction pathways in cancer$145,634
R43 · FY2004 · CA